Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study

Trial Profile

Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Sparsentan (Primary) ; Irbesartan
  • Indications Focal segmental glomerulosclerosis
  • Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
  • Acronyms DUET
  • Sponsors Retrophin
  • Most Recent Events

    • 13 Oct 2017 According to a Retrophin media release, data will be presented at the American Society of Nephrology (ASN) Kidney Week 2017.
    • 25 May 2017 According to a Retrophin media release, results of subgroup analysis from this study will be presented at the 54th European Renal Association European Dialysis and Transplant Association (ERA-EDTA) Congress 2017.
    • 21 Nov 2016 Additional results published in Ligand Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top